Skip to content

Clinical efficacy verification and brain mechanism research on the treatment of treatment-resistant depression through accelerated intermittent theta burst stimulation (aiTBS) targeting the left primary motor cortex (M1)

Clinical efficacy verification and brain mechanism research on the treatment of treatment-resistant depression through accelerated intermittent theta burst stimulation (aiTBS) targeting the left primary motor cortex (M1)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112262
Enrollment
Unknown
Registered
2025-11-12
Start date
2025-11-15
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive symptoms

Interventions

The AI-TBS pseudo-stimulation group:Maintain pseudo stimulus
The aiTBS stimulation group:Active stimulation

Sponsors

Ningbo University Affiliated Kangning Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18–65 years, right-handed; 2. Meet the diagnostic criteria for depression according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 3. HAMD-24 total score >= 20 points; 4. Classified as moderate to severe treatment-resistant according to the Maudsley Staging Method (MSM), with a score higher than 6; 5. Physical examination, medical history, vital signs, routine blood, urine, and stool tests, liver and kidney function, electrolytes, ECG, and EEG are all normal; 6. Fully understand the safety of TMS, willing to actively cooperate with treatment, and informed consent signed by both the patient and their family.

Exclusion criteria

Exclusion criteria: 1. History of severe physical illness and depression caused by other psychoactive substances or non-dependent substances; 2. Patients with metal or electronic devices implanted in the body, such as intracranial metal foreign bodies, cochlear implants, pacemakers, and stents; 3. At risk of epileptic seizures, with a history of brain disease, head trauma, alcohol abuse, abnormal EEG, evidence of brain structural abnormalities on MRI, or a family history of epilepsy; 4. Presence of psychotic symptoms requiring concurrent antipsychotic medication; 5. Received ECT, TMS, or other tES treatments, or systemic psychotherapy within the 3 months prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Assessment of depressive symptoms;

Secondary

MeasureTime frame
Motor behavior ability;Anxiety, insomnia, suicide, and other clinical symptoms;Brain region activation, functional connectivity, cortical plasticity, etc;

Countries

China

Contacts

Public ContactDongsheng Zhou

Ningbo University Affiliated Kangning Hospital

wyzhouds@sina.com+86 574 2630 2565

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026